Anton Ticktin, partner at The Valence Group, discusses how activist investors are targeting companies in Europe and the impact they have on M&A.» Read More
Philip Whitchelo, vice president of strategy and product marketing at Intralinks, discusses the current state of M&A activity.
TJX buys Australian off-price retailer Trade Secret for $80 million.
The CEO of German drugmaker Bayer has quashed any talk of acquiring its competitor Syngenta, which is being pursued by U.S. firm Monsanto.
Belgian chemical group Solvay will buy U.S. peer Cytec for $5.5 billion to boost its presence in lightweight composites for planes and cars.
Marijn Dekkers, CEO of Bayer, says Syngenta wouldn't be a logical acquisition target for Bayer.
Honeywell International said it would buy the utility consumption meter business of Melrose Industries for 3.3 billion pounds ($5.14 billion).
Boyong Liu, equity research analyst at Jefferies, discusses Delta Air Lines' decision to purchase 3.55 percent of China Eastern Airlines.
Delta Air Lines has agreed to buy 3.55 percent of China Eastern Airlines, a move that would make it the first U.S. carrier to own part of a Chinese airline.
Brian Gilmartin, portfolio manager at Trinity Asset Management, discusses the deal between Israel's Teva Pharmaceutical and Allergan's generic pharmaceuticals business.
Teva buys Allergan's generic drug business for $40.5 billion.
McGraw Hill Financial announced plans to acquire SNL Financial in a cash deal valued at approximately $2.225 billion.
Pearson is in talks to sell its 50 percent stake in The Economist to the other shareholders, with one confirming it wants to increase its stake.
Brent Saunders, Allergan president & CEO, discusses the strategy behind selling its generic unit to Teva Pharmaceuticals.
Brent Saunders, Allergan president & CEO, discusses selling Allergan's generic unit to Teva Pharmaceutical for $40.5 billion.
Teva Pharmaceutical Industries will buy the generic drug division of Allergan Plc, reports the "Squawk Box" crew.
Allergan chief Brent Saunders says the sale of its generics business would allow the company to double down on its higher margin branded business.
Sonny Wu, chairman of GSR Capital, explains why the Chinese venture-capital firm is raising $5 billion to acquire companies in technology, internet and biotechnology industries globally.
Teva Pharmaceutical is nearing a deal to acquire Allergan's generics drug unit for between $40bn and $45bn, according to people familiar with the matter. The FT reports.
Pearson is in talks to sell its stake in the Economist Group, to other shareholders in the group, according to people familiar with the situation. The FT reports.
CNBC's Mandy Drury looks ahead to what are likely to be next week's top business and financial stories.